TY - JOUR
T1 - Landmarks for dual biological therapy in inflammatory bowel disease
T2 - Lesson from two case reports of vedolizumab in combination with ustekinumab
AU - Biscaglia, Giuseppe
AU - Piazzolla, Mariano
AU - Cocomazzi, Francesco
AU - Melchionda, Gennaro
AU - De Cata, Angelo
AU - Bossa, Fabrizio
AU - Palmieri, Orazio
AU - Andriulli, Angelo
N1 - Publisher Copyright:
© 2020 Lippincott Williams and Wilkins. All rights reserved.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - Inflammatory bowel disease (IBD) is a chronic and disabling disorder. Severity of IBD is prominent among refractory with patients with concomitant immune-mediated disorders. Among those patients, dual biological therapy (DBT) has been suggested as an alternative approach to spare steroids and avoid surgery. However, pieces of evidence on clinical outcomes among patients receiving DBT are still limited. We present two cases of IBD patients, with dermatological comorbidity, treated with a combination of vedolizumab and ustekinumab, identifying possible landmarks to address therapeutic choice. No patient experienced adverse events in the follow-up period and both obtained complete clinical remission. DBT may be an effective approach to consider in selected patients with refractory IBD with concomitant severe immune-mediated diseases taking into account medical history of the patient, presence, and type of concomitant extraintestinal manifestations, safety profile of selected DBT, licensed therapeutic indications, and costs.
AB - Inflammatory bowel disease (IBD) is a chronic and disabling disorder. Severity of IBD is prominent among refractory with patients with concomitant immune-mediated disorders. Among those patients, dual biological therapy (DBT) has been suggested as an alternative approach to spare steroids and avoid surgery. However, pieces of evidence on clinical outcomes among patients receiving DBT are still limited. We present two cases of IBD patients, with dermatological comorbidity, treated with a combination of vedolizumab and ustekinumab, identifying possible landmarks to address therapeutic choice. No patient experienced adverse events in the follow-up period and both obtained complete clinical remission. DBT may be an effective approach to consider in selected patients with refractory IBD with concomitant severe immune-mediated diseases taking into account medical history of the patient, presence, and type of concomitant extraintestinal manifestations, safety profile of selected DBT, licensed therapeutic indications, and costs.
KW - dual biological therapy
KW - extraintestinal manifestations
KW - immune-mediated diseases
KW - inflammatory bowel disease
UR - http://www.scopus.com/inward/record.url?scp=85094931499&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094931499&partnerID=8YFLogxK
U2 - 10.1097/MEG.0000000000001919
DO - 10.1097/MEG.0000000000001919
M3 - Article
C2 - 32947419
AN - SCOPUS:85094931499
SP - 1579
EP - 1582
JO - European Journal of Gastroenterology and Hepatology
JF - European Journal of Gastroenterology and Hepatology
SN - 0954-691X
ER -